None (ALLR) is a publicly traded company. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Allarity Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new cancer treatments. They utilize a unique "drug response predictor" technology to generate specific companion diagnostics, aiming to identify which patients will best respond to their various oncology therapeutics.
Analysis Summary
Balance sheet quality for ALLR: current ratio of 2.1, net cash position of $13.3M. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Price
| Price | $1.16 |
| Market Cap | $18M |
Financial Health
| Piotroski F-Score | 4 |
| Altman Z-Score | -10.51 |
Price Performance
| 1 month | -14.07% |
| 3 months | -18.88% |
| Year-to-date | +7.41% |
| 1 year | -21.09% |
| 3 years | -99.78% |
52-Week Range
| 52-week High | $1.84 |
| 52-week Low | $0.77 |
| Avg Volume (90d) | 143K |
Related companies: BCTX · CASI · CING · CLSD · CRIS · ENTO · KAPA
More sections of ALLR: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks